PDE4A and chronic obstructive pulmonary disease: Given that ensifentrine is a dual PDE3/PDE4 inhibitor, and that both of these PDEs play an important role in the regulation of CFTR, it is quite likely that the beneficial effects of ensifentrine in COPD may be caused, at least in part, by its effects on CFTR [106,107].